YKL-40 immunoexpression as a prognosticator of mycosis fungoides.
Journal
International journal of dermatology
ISSN: 1365-4632
Titre abrégé: Int J Dermatol
Pays: England
ID NLM: 0243704
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
revised:
01
04
2023
received:
08
02
2023
accepted:
14
06
2023
medline:
22
8
2023
pubmed:
1
7
2023
entrez:
1
7
2023
Statut:
ppublish
Résumé
YKL-40 is a 40 kDa chitinase-like glycoprotein that is predicted to contribute to the pathogenesis of several inflammatory and neoplastic conditions. To assess YKL-40 immunoexpression in different stages of mycosis fungoides (MF) to find out if YKL-40 is playing a possible role in disease pathophysiology and progression. This work included 50 patients with different stages of MF diagnosed on the basis of clinical, histopathological, and both CD4 and CD8 immunophenotyping, in addition to 25 normal control skin. The Immune Reactive Score (IRS) of YKL-40 expression was determined in all specimens and statistically analyzed. YKL-40 expression reported a significant rise in MF lesions compared to control skin. Among MF specimens, the mildest expression was observed in the early patch stage followed by the plaque stage, while the strongest was in tumor stages. Positive correlations were discovered between IRS of YKL-40 expression in MF specimens and patients' age, disease chronicity, clinical staging, and TNMB classification. YKL-40 might participate in MF pathophysiology, and the highest expression is associated with advanced stages of the disease and poor outcomes. Therefore, it might be of value as a prognosticator for monitoring high-risk MF patients and follow-up assessment of treatment success.
Sections du résumé
BACKGROUND
BACKGROUND
YKL-40 is a 40 kDa chitinase-like glycoprotein that is predicted to contribute to the pathogenesis of several inflammatory and neoplastic conditions.
OBJECTIVES
OBJECTIVE
To assess YKL-40 immunoexpression in different stages of mycosis fungoides (MF) to find out if YKL-40 is playing a possible role in disease pathophysiology and progression.
METHODS
METHODS
This work included 50 patients with different stages of MF diagnosed on the basis of clinical, histopathological, and both CD4 and CD8 immunophenotyping, in addition to 25 normal control skin. The Immune Reactive Score (IRS) of YKL-40 expression was determined in all specimens and statistically analyzed.
RESULTS
RESULTS
YKL-40 expression reported a significant rise in MF lesions compared to control skin. Among MF specimens, the mildest expression was observed in the early patch stage followed by the plaque stage, while the strongest was in tumor stages. Positive correlations were discovered between IRS of YKL-40 expression in MF specimens and patients' age, disease chronicity, clinical staging, and TNMB classification.
CONCLUSION
CONCLUSIONS
YKL-40 might participate in MF pathophysiology, and the highest expression is associated with advanced stages of the disease and poor outcomes. Therefore, it might be of value as a prognosticator for monitoring high-risk MF patients and follow-up assessment of treatment success.
Substances chimiques
Chitinase-3-Like Protein 1
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1147-1153Informations de copyright
© 2023 the International Society of Dermatology.
Références
Dai J, Almazan TH, Kim YH. Cutaneous T-cell lymphomas. JAMA Dermatol. 2017;153(6):620.
Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers. J Am Acad Dermatol. 2014;70(2):205.e1-205.e16.
Liu Z, Wu X, Hwang ST, Liu J. The role of tumor microenvironment in mycosis fungoides and sézary syndrome. Ann Dermatol. 2021;33(6):487-96.
Miyagaki T, Sugaya M. Immunological milieu in mycosis fungoides and Sézary syndrome. J Dermatol. 2014;41(1):11-8.
Schultz NA, Johansen JS. YKL-40-a protein in the field of translational medicine: a role as a biomarker in cancer patients? Cancers (Basel). 2010;2(3):1453-91.
Lee CG, Da Silva CA, Dela Cruz CS, Ahangari F, Ma B, Kang MJ, et al. Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. Annu Rev Physiol. 2011;73:479-501.
Ahmed SF, Attia EA, Saad AA, Sharara M, Fawzy H, El Nahrery EM. Serum YKL-40 in psoriasis with and without arthritis; correlation with disease activity and high-resolution power Doppler ultrasonographic joint findings. J Eur Acad Dermatol Venereol. 2015;29(4):682-8.
Khattab FM, Said NM. Chitinase-3-like protein 1 (YKL-40): novel biomarker of lichen planus. Int J Dermatol. 2019;58(9):993-6.
Salomon J, Piotrowska A, Matusiak Ł, Dzięgiel P, Szepietowski JC. Chitinase-3-like protein 1 (YKL-40) expression in squamous cell skin cancer. Anticancer Res. 2018;38(8):4753-8.
Ismail H, Helby J, Hölmich LR, Chakera AH, Bastholt L, Klyver H, et al. Measured and genetically predicted plasma YKL-40 levels and melanoma mortality. Eur J Cancer. 2019;121:74-84.
Suzuki H, Boki H, Kamijo H, Nakajima R, Oka T, Shishido-Takahashi N, et al. YKL-40 promotes proliferation of cutaneous T-cell lymphoma tumor cells through extracellular signal-regulated kinase pathways. J Invest Dermatol. 2020;140(4):860-8.
Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713-22.
Ortonne N, Buyukbabani N, Delfau-Larue MH, Bagot M, Wechsler J. Value of the CD8-CD3 ratio for the diagnosis of mycosis fungoides. Mod Pathol. 2003;16(9):857-62.
Bian B, Li L, Yang J, Liu Y, Xie G, Zheng Y, et al. Prognostic value of YKL-40 in solid tumors: a meta-analysis of 41 cohort studies. Cancer Cell Int. 2019;19:259.
Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):194-202.
Kzhyshkowska J, Yin S, Liu T, Riabov V, Mitrofanova I. Role of chitinase-like proteins in cancer. Biol Chem. 2016;397(3):231-47.
Biggar RJ, Johansen JS, Smedby KE, Rostgaard K, Chang ET, Adami HO, et al. Serum YKL-40 and interleukin 6 levels in Hodgkin lymphoma. Clin Cancer Res. 2008;14(21):6974-8.
El-Galaly TC, Bilgrau AE, Gaarsdal E, Klausen TW, Pedersen LM, Nielsen KR, et al. Circulating tumor necrosis factor-α and YKL-40 level is associated with remission status following salvage therapy in relapsed non-Hodgkin lymphoma. Leuk Lymphoma. 2015;56(8):2476-8.
Shao R, Hamel K, Petersen L, Cao QJ, Arenas RB, Bigelow C, et al. YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene. 2009;28(50):4456-68.
Kawada M, Seno H, Kanda K, Nakanishi Y, Akitake R, Komekado H, et al. Chitinase 3-like 1 promotes macrophage recruitment and angiogenesis in colorectal cancer. Oncogene. 2012;31(26):3111-23.
Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol. 2003;139(7):857-66.
Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010;28(31):4730-9.
Lebowitz E, Geller S, Flores E, Pulitzer M, Horwitz S, Moskowitz A, et al. Survival, disease progression and prognostic factors in elderly patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of 174 patients. J Eur Acad Dermatol Venereol. 2019;33(1):108-14.
Francescone RA, Scully S, Faibish M, Taylor SL, Oh D, Moral L, et al. Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma. J Biol Chem. 2011;286(17):15332-43.
Kang K, Kim K, Lee S-R, Kim Y, Lee JE, Lee YS, et al. Selection and characterization of YKL-40-targeting monoclonal antibodies from human synthetic fab phage display libraries. Int J Mol Sci. 2020;21(17):6354.